GelMEDIX

GelMEDIX, a Harvard/MEEI spinout, offers a transformative solution to corneal repair through sustained drug delivery and novel light-activated biomaterials.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded April 2020
  • Employees 1
  • Incorporation Type Not Incorporated
  • Website gelmedix.com

Company Summary

GelMEDIX, founded by a world-leading ophthalmologic surgeon at Harvard and bioengineers at UCLA, addresses significant problems in ophthalmology - corneal injuries and complicated ophthalmic drug treatment regimens. The GelMEDIX platform is based on light activated biomaterial with three unique properties: exceptional tissue adhesion, tunable drug elution, and high biocompatibility. The market potential is >>$1b.

Team

Advisors

  • Reza Dana
    Unconfirmed
    Nasim Annabi
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free